Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.

Tanaka H, Fukushima H, Kijima T, Nakamura Y, Yajima S, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y.

Int J Urol. 2020 Jan 19. doi: 10.1111/iju.14179. [Epub ahead of print]

PMID:
31957164
2.

Editorial Comment to Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guérin?

Fukushima H, Fujii Y.

Int J Urol. 2020 Jan;27(1):75. doi: 10.1111/iju.14144. Epub 2019 Oct 29. No abstract available.

PMID:
31661718
3.

A young female case of primary renal carcinoid tumor mimicking fat-poor angiomyolipoma.

Kato R, Fukushima H, Kobayashi M, Kawano K, Morimoto S.

Int Cancer Conf J. 2018 Aug 20;7(4):156-158. doi: 10.1007/s13691-018-0341-2. eCollection 2018 Oct.

4.

Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma.

Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

Int J Urol. 2019 Aug;26(8):820-826. doi: 10.1111/iju.14022. Epub 2019 May 28.

PMID:
31140215
5.

Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy?

Nakanishi Y, Ito M, Fukushima H, Yokoyama M, Kataoka M, Ikuta S, Sakamoto K, Takemura K, Suzuki H, Tobisu KI, Koga F.

Clin Genitourin Cancer. 2019 Jun;17(3):e664-e671. doi: 10.1016/j.clgc.2019.03.011. Epub 2019 Mar 27.

PMID:
31003892
6.

Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma.

Fukushima H, Fujii Y, Koga F.

Int J Mol Sci. 2019 Feb 11;20(3). pii: E760. doi: 10.3390/ijms20030760. Review.

7.

Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.

Takemura K, Fukushima H, Ito M, Kataoka M, Nakanishi Y, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Urol Oncol. 2019 Feb;37(2):108-115. doi: 10.1016/j.urolonc.2018.11.002. Epub 2018 Nov 24.

PMID:
30478012
8.

Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.

Fukushima H, Takemura K, Suzuki H, Koga F.

Int J Mol Sci. 2018 Oct 1;19(10). pii: E2999. doi: 10.3390/ijms19102999. Review.

9.

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.

Koga F, Takemura K, Fukushima H.

Int J Mol Sci. 2018 Sep 15;19(9). pii: E2777. doi: 10.3390/ijms19092777. Review.

10.
11.
12.

[PRIMARY MALIGNANT MELANOMA OF THE FEMALE URETHRA: A CASE REPORT].

Suzuki H, Nakanishi Y, Yoshino K, Kataoka M, Fukushima H, Tobisu K, Koga F.

Nihon Hinyokika Gakkai Zasshi. 2018;109(2):111-115. doi: 10.5980/jpnjurol.109.111. Japanese.

14.

Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu KI, Fujii Y, Koga F.

Urol Oncol. 2018 Apr;36(4):156.e9-156.e16. doi: 10.1016/j.urolonc.2017.09.016. Epub 2017 Oct 17.

PMID:
29051030
15.

Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes.

Nishizawa T, Yoshida S, Koga F, Tanaka H, Kaga M, Watanabe K, Fukushima H, Nakanishi Y, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K.

Clin Imaging. 2017 Jul - Aug;44:121-126. doi: 10.1016/j.clinimag.2017.05.004. Epub 2017 May 5.

PMID:
28505504
16.

Impact of sarcopenia in the management of urological cancer patients.

Fukushima H, Koga F.

Expert Rev Anticancer Ther. 2017 May;17(5):455-466. doi: 10.1080/14737140.2017.1301209. Epub 2017 Mar 8. Review.

PMID:
28271727
17.

Retroperitoneal Teratoma in an Adult: A Potential Pitfall in the Differential Diagnosis of Adrenal Myelolipoma.

Kataoka M, Fukushima H, Nakanishi Y, Yokoyama M, Funata N, Motoi T, Tobisu KI, Koga F.

Case Rep Urol. 2016;2016:5141769. Epub 2016 Oct 20.

18.

Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.

Fukushima H, Nakanishi Y, Kataoka M, Tobisu KI, Koga F.

Clin Genitourin Cancer. 2017 Apr;15(2):e229-e238. doi: 10.1016/j.clgc.2016.08.004. Epub 2016 Aug 10.

PMID:
27601279
19.

Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.

Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F.

Cancer Med. 2016 Sep;5(9):2213-20. doi: 10.1002/cam4.795. Epub 2016 Jun 28.

20.

Prognostic significance of intensive local therapy to bone lesions in renal cell carcinoma patients with bone metastasis.

Fukushima H, Hozumi T, Goto T, Nihei K, Karasawa K, Nakanishi Y, Kataoka M, Tobisu K, Koga F.

Clin Exp Metastasis. 2016 Oct;33(7):699-705. doi: 10.1007/s10585-016-9805-y. Epub 2016 Jun 17.

PMID:
27316704

Supplemental Content

Loading ...
Support Center